ARTICLE | Emerging Company Profile
Kivu: Advancing safer ADCs against established targets
Company launches with $92 million to develop antibody-drug conjugates spun out of Synaffix
October 29, 2024 12:20 AM UTC
With backing from Novo Ventures, a pharma veteran as president and COO, and preclinical antibody-drug conjugates, Kivu Bioscience Inc. is putting the non-core asset spinout model to the test. It’s also on a mission to elevate tolerability as a priority for the next-generation of ADCs.
The biotech was launched with a license to three antibody-drug conjugates that were constructed using the GlycoConnect site-specific conjugation technology of Synaffix B.V., then spun out when Synaffix was acquired by Lonza Group Ltd. (SIX:LONN)...